IP Library Granted Patent US 7,358,076
Granted Patent B2
US 7,358,076 · App. 10/372,098 · Granted Apr 15, 2008

Sublancin lantibiotic produced by

Assignee: The University of Maryland
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,358,076
App. No.
10/372,098
Granted
Apr 15, 2008
Kind
B2
Abstract

An antimicrobial peptide produced by Bacillus subtilis 168 was isolated and characterized and named sublancin 168. The invention includes DNA encoding for the sublancin 168 peptides and peptides which are at least 80% identical to the sublancin 168 peptide. The peptides may be administered as anti-bacterials, or may be used in food preservation. The peptides may also be co-administered with other lantibiotics (such as nisin and subtilin), or with known antibiotics.

Claims (7)

1. A method for inhibiting the spore outgrowth of gram positive bacteria comprising contacting said bacteria with a composition comprising an isolated peptide having the amino acid sequence of SEQ ID NO:18.

2. A method for inhibiting the spore outgrowth of gram positive bacteria comprising contacting said bacteria with a composition comprising an isolated peptide having the amino acid sequence of SEQ ID NO:18, and wherein the composition further comprises an active agent selected from the group consisting of a lantibiotic and an antibiotic.

3. A preserved food, comprising a food and a bacterial-growth-inhibiting effective amount of an isolated peptide having the amino acid sequence of SEQ ID NO:18.

4. A composition suitable for killing or inhibiting growth of bacteria, comprising an isolated peptide having the amino acid sequence of SEQ ID NO:18 and a carrier.

5. A composition suitable for killing or inhibiting growth of bacteria, comprising an isolated peptide having the amino acid sequence of SEQ ID NO:18, an active agent selected from the group consisting of a lantibiotic and an antibiotic, and a carrier.

6. The composition of claim 5 , wherein the active agent is nisin.

7. The composition of claim 5 , wherein the active agent is subtilin.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 29, 2022
From: UNIVERSITY OF MARYLAND
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060045/0653 →
CONFIRMATORY LICENSE Recorded Jun 14, 2017
From: UNIV OF MARYLAND, COLLEGE PARK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042806/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2008
From: HANSEN, J. NORMAN
To: UNIVERSITY OF MARYLAND-OFFICE OF TECHNOLOGY COMMERCIALIZATION
Reel/Frame 020501/0629 →
Continuity (3)
Division 0946247800
Provisional Application 6005303500 · Jul 18, 1997
Related Publication 20030166835A1 · Sep 4, 2003